Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (1033)	5/17/1998 8:41:00 PM
From: marc ultra	Respond to of 2135

It will be interesting since I believe they were planning toxicology studies in monkeys or some such primate before giving it to any human. This makes me think this bunch is literally going to be on their deathbed as dosing etc. is going to be extrapolated from paltry data. If they get lucky and some do very well I wouldn't expect to hear anything for a long time as the appearance of a terminal patient dancing in front of a CNN camera would cause a crush of people demanding drug that hasn't gone through most basic tests, isn't available in any quantities and probably won't even have any real protocols written yet. Any of these initial bunch are gong to be kept in the hospital, studied and tested up the wazoo for a very long time or until autopsy

To: LTK007 who wrote (1033)	5/17/1998 9:17:00 PM
From: Andreas Helke	Read Replies (1) \| Respond to of 2135

I pretty much expected that angiostatin and endostatin would be tested in humans as soon as possible. If all goes well we may know if those angiogenesis inhibitors work in humans even before EntreMed finishes preclinical development and toxicology testing and files its IND. I had hoped that I would have some more time to accumulate some more cheap EntreMed shares and to decide if it would be prudent to lighten up on Agouron and Ligand which are the cancer biotechs were I have really big positions now. But I do now fear that EntreMed will stay expensive until we know that those angiogenesis inhibitors are not suitable drugs. If that happens I would no longer be interested in EntreMed stock. But even if the preliminary tests do not work well there is still the chance that the drug candidates turn out to be successful drugs in some cancers during the regular clinical development. Andreas

To: LTK007 who wrote (1033)	5/19/1998 5:38:00 PM
From: Andreas Helke	Respond to of 2135

It turned out that the time line of december for first human tests was too optimistic. Human tests will begin when researchers have figured out how to make enough of those proteins which seem to be unstable and difficult to work with. Andreas From Message 4517718 "Pluda also said reports last weekend that human testing of angiostatin and endostatin could begin as early as December were wrong. He said both the cancer institute and Entremed Inc. are working to figure out the best way to produce the drugs, but it will be a year before enough is available to try on people."